Alphatec Holdings, Inc. (ATEC) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session indicate a positive outlook: increased revenue guidance, positive cash flow expectations, strong market position, and upcoming product launches like Valence. While some responses were vague, the overall sentiment from management and analysts is optimistic. The raised guidance and strong market position, coupled with the company's strategic growth and innovation focus, suggest a positive impact on the stock price, particularly given its small-cap status.
Key Financial Performance
Total Revenue $197 million, up $46 million and 30% compared to the prior year period. Reasons for change: Driven by strong surgeon adoption, increased procedural volume, and same-store sales growth.
Surgical Revenue $177 million, grew 31% compared to the prior year period. Reasons for change: Procedural volume growth of 28% driven by strong surgeon adoption and increased utilization of portfolio offerings.
EOS Revenue $20 million, up 29% compared to the prior year period. Reasons for change: Strong demand in the U.S. market and increased surgeon usage of EOS Insight.
Adjusted EBITDA $26 million, 13% of revenue, improved by 840 basis points year-over-year. Reasons for change: Disciplined headcount additions, infrastructure leverage, and improved operating margin.
Free Cash Flow $5 million, positive for the second consecutive quarter. Reasons for change: Improved cash generation and efficiency in revenue-generating assets.
Non-GAAP Gross Margin 70%, up 80 basis points compared to the previous year. Reasons for change: Product mix and volume leverage.
Non-GAAP R&D Expense $15 million, up by more than $2 million year-over-year. Reasons for change: Increased investment in innovation to drive future growth.
Non-GAAP SG&A Expense $112 million, approximately 57% of sales, improved by 980 basis points year-over-year. Reasons for change: Foundational infrastructure investments and deliberate headcount additions.
Trailing 12 Months Adjusted EBITDA $81 million, 11% of revenue. Reasons for change: Consistent profitability progress and disciplined execution.
Cash on Hand $156 million, with total cash and available cash at $216 million. Reasons for change: Positive free cash flow and efficient cash management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Products: Multiple new products forthcoming, including a mechanized arm, IdentiTi II, and corpectomy. Expansion of indications and increasing complexity in lateral procedures. SafeOp's expanded application in cervical spine.
Market Expansion: Strong surgeon adoption with 26% increase in new surgeon users. Same-store sales in the U.S. grew 30% year-over-year. EOS revenue increased by 29%, driven by U.S. market demand. International market investments showing positive results.
Operational Efficiencies: Non-GAAP gross margin at 70%, up 80 basis points year-over-year. SG&A expenses reduced to 57% of sales from 67% in the prior year. Positive free cash flow of $5 million in Q3, with trailing 12 months free cash flow turning positive for the first time.
Strategic Shifts: Focus on proceduralization, particularly in lateral, cervical, and deformity segments. Integration of technology like EOS, Valence, and SafeOp to enhance surgical outcomes. Long-term infrastructure investments in data-driven decision-making and international markets.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Tariffs: The company is absorbing the impact of expected tariffs in the second half of the year, which could affect cost of goods sold by low single-digit millions of dollars for the full year.
Supply Chain Investments: The company has forward invested in instruments and inventory, which could pose risks if demand does not meet expectations or if there are inefficiencies in asset utilization.
Market Adoption of New Technologies: The success of new technologies like Valence and EOS depends on surgeon adoption and market acceptance, which could impact revenue growth if adoption is slower than anticipated.
Competitive Pressures: The company acknowledges the complexity of the spine market and the need for continuous innovation to maintain its leadership position, which could be challenged by competitors.
Economic Uncertainties: While not explicitly mentioned, the reliance on surgeon adoption and procedural growth could be impacted by broader economic conditions affecting healthcare spending.
Operational Scalability: The company has made significant infrastructure investments, and its ability to scale profitably depends on the efficient utilization of these resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company has raised its full-year revenue guidance by $18 million to $760 million. Surgical revenue is expected to be approximately $684 million, and EOS revenue is projected at $76 million.
Case Volume Growth: Case volume is expected to grow in the low 20% range year-over-year.
Case ASP Growth: Case ASP is expected to grow in the low single digits year-over-year.
Free Cash Flow Guidance: The company expects fourth-quarter free cash flow to range from positive $6 million to positive $8 million. For the full year 2025, positive free cash flow is anticipated.
Adjusted EBITDA Guidance for 2025: The company expects adjusted EBITDA of $91 million, an $8 million increase from prior guidance, with an adjusted EBITDA margin of 12% for the full year.
Long-Term Financial Commitments: The company aims to achieve $1 billion in revenue, 18% adjusted EBITDA, and $65 million of free cash flow by 2027.
Product and Market Expansion: Multiple new products are forthcoming, including a mechanized arm and IdentiTi II. The company is also expanding its proceduralization efforts to cervical and deformity markets.
Technology Integration: The company plans to integrate data-driven decision-making into spine surgery, leveraging platforms like EOS, Valence, and SafeOp.
Deformity Market Growth: The company is in the early stages of accelerating its deformity market presence through AI-driven alignment, pre-op assessment, and patient-specific implants.
Valence System Launch: The Valence system is expected to launch in Q4 2025, with significant influence anticipated in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do you see next year playing out from a cash flow perspective given the strength over the last 2 quarters?
A:Management expects cash flow expectations for next year to be in the $20 million range on free cash flow, on the path to $65 million of free cash flow next year. They are not yet providing guidance but consider this a good construct.
Q:Can we expect an update to your long-range plan (LRP) next year given that you're tracking well ahead of your plan?
A:Management is contemplating the right time for an update and believes towards the end of next year, as they enter 2027 and get 2026 mostly under their belt, would be a good time for an update.
Q:What are your thoughts on the competitive landscape and recent consolidations in the spine market?
A:Management welcomes market disruption and believes these dynamics take years to play out. They are focused on their own catalysts and being opportunistic with sales hires, viewing the disruption as an opportunity.
Q:What benefits does Valence bring to the lateral space and how does it impact efficiency and adoption?
A:Valence is seen as a driver of procedures at 4, 5 and above, aiming to democratize surgery and integrate technological elements into the workflow. Management highlighted its neurophysiology capabilities and mechanized arm as key differentiators, contributing to predictability and efficiency for both experienced and new users.
Q:What are you seeing in the spine market and competitive dynamics? Who are you taking excess share from?
A:Management attributes their performance to the foundation built over the years and believes they are taking share from various competitors. They see the spine market as stable and are adding new surgeons, which is a proxy for future business.
Q:How do you balance growth versus profitability, and how does your average rep per case impact profitability?
A:Management prioritizes growth and investment in innovation while maintaining profitability. They aim to self-fund growth through adjusted EBITDA and leverage overhead. Their high average selling price (ASP) per case reflects the adoption of their procedural thesis, which integrates multiple products for predictability.
Q:What is the outlook for Valence and the size of the ASC opportunity?
A:Management expects Valence to have a significant impact starting in 2026, with demand already evident. They view it as an integrated tool for surgery rather than a capital sales opportunity, focusing on driving surgical volume.
Q:What is your outlook on international expansion and its contribution to the long-range plan?
A:Management feels on track with their long-range plan commitments, which include $30 million of international surgical revenue by 2027. They are taking a narrow and deep approach to international expansion.
Q:Why is the implied guidance for Q4 smaller than expected, and how should we think about the outlook for 2026?
A:Management believes the $18 million lift in guidance is strong and prudent, implying 20% year-over-year growth in surgical revenue. They suggest using the $120 million to $130 million annual growth range as a reference for 2026.
Q:What is the traction in the deformity segment and its contribution to revenue growth?
A:Management sees deformity as in its infancy but with significant potential, driven by EOS and EOS Insight. They are focusing on idiopathic and adult deformity, with multiple products in development to enhance preoperative and intraoperative elements.
Q:How are you being disciplined in sales team additions, and will you add to the capital sales team for Valence?
A:Management has an algorithm to minimize the time from hire to effectiveness, focusing on markets where they are underrepresented. They plan to add some capital sales heads for Valence but expect existing salespeople to manage most cases.
Q:What are the primary drivers behind EOS sales, and has the target market expanded beyond academic centers?
A:EOS sales are driven by EOS Insight and its ability to create informatics around full-body scans. While initially focused on academic centers, there is growing interest from private institutions and upgrades from pediatric centers.
Q:What is the durability of new surgeon adoption growth, and where will future growth come from?
A:Management sees new surgeon adoption as a proxy for future growth, with established territories driving same-store sales. They are also entering new markets, which will contribute to surgeon adoption and growth.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the question about the funnel of orders for Valence and the size of the ASC opportunity, providing only general comments about demand and the democratization of surgery. Additionally, they did not provide specific details on the timing and scale of deformity product launches or the exact impact of EOS on revenue growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASP digit
ATEC number
ATEC result
Audio Gap
CEO Miles
CFO Koning
EOS Insight
EOS raise
Gap cash
Insight infrastructure
Insight position
Koning Miles
Lacie ATEC
Miles CFO
Miles Lacie
PL period
President medtech
RD area
RD investment
addition combination
addition type
adoption attractiveness
algorithm EOS
area opportunity
asset dollar
cash month
club
end cash
flow cash
history
instrument inventory
investment sale
month cash
number surgeon
offering
prioritization
tariff
ATEC Transcript
Alphatec Holdings, Inc. (ATEC) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral5-12
Alphatec Holdings, Inc. (ATEC) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary indicates a revenue shortfall due to underperformance in EOS sales, which negatively impacts financial results and strategic goals. The lack of discussion on strategic initiatives and shareholder returns further weakens the sentiment. The absence of positive catalysts like new partnerships or optimistic guidance, coupled with unclear management responses in the Q&A, suggests a negative market reaction. Given the market cap, the stock is likely to experience a moderate negative movement.
Alphatec Holdings, Inc. (ATEC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Alphatec Holdings, Inc. (ATEC) Q4 2025 Earnings Call Transcript
Positive2-24
The company's earnings call revealed strong financial performance, including a 25% increase in annual revenue and a 61% increase in Q4 adjusted EBITDA. The raised guidance for 2026 and positive free cash flow are optimistic indicators. Despite some risks in adoption rates and regulatory challenges, the overall sentiment is positive, supported by strategic growth investments and improved margins. Given the market cap of approximately $1.45 billion, these factors suggest a positive stock price reaction in the short term.
ATEC Slides
ATEC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
